— Know what they know.
Not Investment Advice

VVOS NASDAQ

Vivos Therapeutics, Inc.
1W: +7.9% 1M: -12.1% 3M: -68.5% YTD: -94.0% 1Y: -95.2% 3Y: -96.8% 5Y: -99.9%
$0.15
+0.00 (+1.88%)
 
Weekly Expected Move ±12.2%
$0 $0 $0 $0 $0
NASDAQ · Healthcare · Medical - Devices · Tech Score Sell · Power 31 · $2.1M mcap · 10M float · 95.21% daily turnover · Short 41% of daily vol
Smart Money Score
Watch 0
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$2.1M
52W Range0.1289-3.42
Volume651,670
Avg Volume9,961,243
Beta6.00
Dividend—
Analyst Ratings
6 Buy 0 Hold 0 Sell
Consensus Buy
Company Info
CEOR. Kirk Huntsman
Employees268
SectorHealthcare
IndustryMedical - Devices
IPO Date2020-12-11
Websitevivos.com
7921 Southpark Plaza
Littleton, CO 80120
US
866 908 4867
About Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.

Recent Insider Trades

NameTypeSharesPriceDate
JOHNSON GREGG C A-Award 12,000 $0.18 2026-09-14
SOKOLOW LEONARD J A-Award 12,000 $0.18 2026-09-14
Amman Bradford K. A-Award 250,000 $0.41 2026-07-31
Amman Bradford K. A-Award 150,000 $0.41 2026-07-31
Huntsman Ronald Kirk J-Other 85,910 — 2026-06-30

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms